Clinical trials: Peritoneal Malignancy
Cancer
Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer
Anastomotic leakage is a serious complication after LAR with high morbidity and mortality rates. Early diagnosis and treatment is mandatory.
- Trial name
- NCT01062334
- Testing
- Peritoneal Microdialysis, CT-scan, leakage scoring
- Where
- 2 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Odense University Hospital
Colorectal Cancer
A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.
Assuming that the objective response rate (ORR) of neoadjuvant chemotherapy in patients with colorectal cancer peritoneal metastasis is approximately 0.40 , a total sample size of 30 patients is required.
- Trial name
- NCT07268677
- Testing
- pirfenidone plus sintilimab combined with standard neoadjuvant chemotherapy
- Volunteers
- 30 people
- Sponsor
- Guoxiang Cai
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
This phase II trial tests how well concentrating heated (hyperthermic) chemotherapy in the area that contains the abdominal organs (intraperitoneal [IP]) at the time of surgery works in treating patients with gastric or…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07139951
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Intestinal Obstruction, Carcinoma
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.
- Conditions
- Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms
- Trial name
- NCT00216372
- Testing
- Lanreotide (microparticle formulation)
- Where
- 53 sites in Belgium, France and 1 more
- Volunteers
- 80 people
- Sponsor
- Ipsen
Gastric Cancer (GC), Pancreatic Cancer
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver.
- Conditions
- Gastric Cancer (GC), Pancreatic Cancer, Colorectal Cancer
- Trial name
- PREDIPER (NCT07574957)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Peritoneal Carcinomatosis
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity.
- Trial name
- NCT04950166
- Testing
- pegsitacianine
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoNano Medicine, Inc.
Colorectal Neoplasm
SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (SOX) and Oxaliplatin and Capecitabine (XELOX) in patients with peritoneal metastasis of colorectal cancer.
- Trial name
- NCT02870153
- Testing
- SOX, XELOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First People's Hospital of Changzhou
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Anxiety, Fatigue
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
This clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer.
- Conditions
- Anxiety, Fatigue, Nausea and Vomiting, Neurotoxicity Syndrome
- Trial name
- NCT01372787
- Testing
- Assessment of Therapy Complications, Medical Chart Review, Quality-of-Life Assessment
- Where
- 144 sites in United States
- Volunteers
- 103 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- FORWARD I (NCT02631876)
- Testing
- Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin
- Where
- 131 sites in United States, Belgium and 11 more
- Volunteers
- 366 people
- Sponsor
- ImmunoGen, Inc.
Colorectal Cancer, Peritoneal Metastases
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
A dose titration study and a combined superiority registry-based open-label randomized control trial is planned to answer the trial objectives. The study will be registry-based to allow simpler and more comprehensive follow-up.
- Trial name
- EFFIPEC (NCT04861558)
- Testing
- 5Fluorouracil, Irinotecan, Oxaliplatin
- Where
- 5 sites in India, Sweden
- Volunteers
- 213 people
- Sponsor
- Uppsala University
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor
International PPB/DICER1 Registry
PPB has strong genetic implications, with a unique set of conditions in an individual or their family, occurring mostly in childhood and adolescence.
- Conditions
- Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma
- Trial name
- NCT03382158
- Where
- United States
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well RO4929097 works in treating patients with recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer
- Trial name
- NCT01175343
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 12 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01167725
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Where
- 2 sites in United States
- Volunteers
- 340 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms, Ovarian Neoplasms
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and…
- Conditions
- Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
- Trial name
- NCT01279291
- Testing
- KHK2866, Gemcitabine and Carboplatin, paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
This phase II trial is studying how well SJG-126 works in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that did not respond to previous treatment with cisplatin or carboplatin.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01200797
- Testing
- SJG-136, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well EGEN-001 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that is persistent or has come back.
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01118052
- Testing
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00006235
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cancer
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
This is an open-label study of liposomal doxorubicin with or without volociximab for the treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer relapsed after prior therapy with…
- Trial name
- NCT00635193
- Testing
- M200 (Volociximab), Liposomal Doxorubicin
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 138 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.